Clozapine for treatment-resistant agitation in dementia.

Clozapine for treatment-resistant agitation in dementia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clozapine for treatment-resistant agitation in dementia. Abstract Text:

Hochang B Lee,Jennifer A Hanner,Jessica L Yokley,Brian Appleby,Lisa Hurowitz,Constantine G Lyketsos,Hochang B Lee,Jennifer A Hanner,Jessica L Yokley,Brian Appleby,Lisa Hurowitz,Constantine G Lyketsos,

Few studies have examined the potential role of clozapine in treatment of agitation in dementia patients who have previously failed to respond to standard pharmacotherapy. We conducted a systematic chart review of all elderly patients admitted to our inpatient unit between 2001 and 2004. Of them, 16 dementia patients were treated with clozapine for treatment-resistant agitation, and their charts were blindly rated by 3 clinicians on the Clinical Global Impression (CGI) Scale, Brief Agitation Rating Scale (BARS), and the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF). Overall, clozapine therapy seemed beneficial in treatment-resistant agitation in dementia patients.

Clozapine for treatment-resistant agitation in dementia. Publishing Authors By Initials

HB Lee,JA Hanner,JL Yokley,B Appleby,L Hurowitz,CG Lyketsos,HB Lee,JA Hanner,JL Yokley,B Appleby,L Hurowitz,CG Lyketsos,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clozapine for treatment-resistant agitation in dementia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of geriatric psychiatry and neurology

VOLUME: 20

Page Numbers: 178-82

Journal Abbreviation:

ISSN: 0891-9887

DAY: 22

MONTH: Sep

YEAR: 2007

Clozapine for treatment-resistant agitation in dementia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8805645

Clozapine for treatment-resistant agitation in dementia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clozapine for treatment-resistant agitation in dementia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clozapine for treatment-resistant agitation in dementia.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 550 N Broadway, Suite 308, Baltimore, MD 21205, USA. hochang@jhmi.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Geriatr Psychiatry Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clozapine for treatment-resistant agitation in dementia Related Publications

• A clinical approach to mild cognitive impairment.
• A comparison of small and large assisted living facilities for the diagnosis and care of dementia: the Maryland Assisted Living Study.
• Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
• Apolipoprotein E genotype and lifetime cognitive decline.
• Clozapine for treatment-resistant agitation in dementia.
• Depression and type 2 diabetes mellitus: the multiethnic study of atherosclerosis.
• Depression in assisted living is common and related to physical burden.
• Differentiating Alzheimer's disease and frontotemporal dementia: receiver operator characteristic curve analysis of four rating scales.
• Epidemiology of apathy in older adults: the Cache County Study.
• Examining a bidirectional association between depressive symptoms and diabetes.
• Influence of social network characteristics on cognition and functional status with aging.
• Mild cognitive impairment: searching for the prodrome of Alzheimer's disease.
• Prevalence of psychiatric disorders in Athens. A community study.
• Race and restless legs syndrome symptoms in an adult community sample in east Baltimore.
• Rates of depression in individuals with pathologic but not clinical Alzheimer disease are lower than those in individuals without the disease: findings from the Baltimore Longitudinal Study on Aging (BLSA).
• Restless Legs Syndrome is Associated with DSM-IV Major Depressive Disorder and Panic Disorder in the Community.
• Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study.
• The association between activity participation and time to discharge in the assisted living setting.
• Vascular factors predict rate of progression in Alzheimer disease.